BACKGROUND: @entity111 is a characteristic clinical sign of @entity272 including @entity483 ( @entity483 ) in the @entity235 . @entity69616 is a cytokine found in the serum of some @entity235 with @entity483 and can induce @entity11782 in laboratory @entity235 . HYPOTHESIS/OBJECTIVES: The objectives were to characterize an @entity69616 -induced @entity111 model by evaluating the efficacy of @entity617 , @entity619 and @entity69617 , and to compare the speed of anti-pruritic effects of @entity69617 against those of @entity617 and @entity619 . ANIMALS: Purpose-bred @entity235 were used in all studies. METHODS: Randomized, blinded, placebo-controlled studies were designed to evaluate and compare the anti-pruritic properties of @entity617 , @entity619 and @entity69617 following a single intravenous injection of recombinant @entity235 @entity69616 . Video surveillance was used to monitor and score @entity11782 in study animals. RESULTS: @entity617 [0.5 mg/kg, per os (p.o.)] reduced @entity69616 -induced @entity111 when given 10 h prior to observation. When the time interval between drug treatment and observation was shortened to 1 h, @entity619 (0.2 mg/kg, intramuscular) but not @entity617 (0.25 or 0.5 mg/kg, p.o.) reduced @entity69616 -induced @entity111 . @entity69617 (0.4 mg/kg, p.o.) reduced @entity111 when given 1, 6, 11 and 16 h prior to the observation period, and the anti-pruritic activity of @entity69617 was greater when compared to @entity617 and @entity619 at all time points assessed. CONCLUSION AND CLINICAL IMPORTANCE: The efficacy of @entity617 , @entity619 and @entity69617 in the @entity69616 -induced @entity111 model gives confidence that this may be a relevant model for acute @entity111 associated with @entity56 including @entity483 and can be used to evaluate novel compounds or formulations.

@entity69616 -induced XXXX in @entity235 : a novel experimental model to evaluate anti-pruritic effects of @entity235 therapeutics.

@entity483 :: ('MESH:D003876', 'Disease') :: ['atopic dermatitis', 'AD'] @entity11782 :: ('MESH:C535817', 'Disease') :: ['pruritic behaviours'] @entity235 :: ('9615', 'Species') :: ['canine', 'beagle dogs', 'dog', 'dogs'] @entity69617 :: ('MESH:C588062', 'Chemical') :: ['Oclacitinib', 'oclacitinib'] @entity111 :: ('MESH:D011537', 'Disease') :: ['Pruritus', 'pruritus'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic dermatitis'] @entity272 :: ('MESH:D012871', 'Disease') :: ['allergic skin conditions'] @entity69616 :: ('100302725(Tax:9615)', 'Gene') :: ['IL-31'] @entity617 :: ('MESH:D011239', 'Chemical') :: ['Prednisolone', 'prednisolone']
@entity111 :: (MESH:D011537,Disease) :: ['pruritus']
